Evidence map›Paper›PMID 39948275›Full record

ArticleCommunications biology2025

A transformer-based semi-autoregressive framework for high-speed and accurate de novo peptide sequencing.

Yang Zhao, Shuo Wang, Jinze Huang, Bo Meng, Dong An, Xiang Fang, Yaoguang Wei, Xinhua Dai

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yang Zhao *College of Information and Electrical Engineering, China Agricultural University, Beijing, 100083, China. Zhaoy@nim.ac.cn.ORCID http://orcid.org/0000-0003-1444-5927
Shuo Wang *College of Information and Electrical Engineering, China Agricultural University, Beijing, 100083, China.
Jinze HuangCollege of Information and Electrical Engineering, China Agricultural University, Beijing, 100083, China.
Bo MengTechnology Innovation Center of Mass Spectrometry for State Market Regulation, Center for Advanced Measurement Science, National Institute of Metrology, Beijing, 100029, China.
Dong AnCollege of Information and Electrical Engineering, China Agricultural University, Beijing, 100083, China.
Xiang FangTechnology Innovation Center of Mass Spectrometry for State Market Regulation, Center for Advanced Measurement Science, National Institute of Metrology, Beijing, 100029, China. fangxiang@nim.ac.cn.
Yaoguang WeiCollege of Information and Electrical Engineering, China Agricultural University, Beijing, 100083, China. wyg@cau.edu.cn.ORCID http://orcid.org/0000-0003-4888-8558
Xinhua DaiTechnology Innovation Center of Mass Spectrometry for State Market Regulation, Center for Advanced Measurement Science, National Institute of Metrology, Beijing, 100029, China. dxinhua@foxmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

De novo peptide sequencing directly identifies peptides from mass spectrometry data, playing a critical role in discovering novel proteins and analyzing complex biological samples without reliance on existing databases. To address challenges in both speed and accuracy, a transformer-based model, TSARseqNovo, incorporates two key innovations: a Semi-Autoregressive decoder for parallel prediction of multiple amino acids and a Masking Refinement decoder for refining low-confidence predictions. These features significantly enhance sequencing efficiency and accuracy. Evaluations on the Nine-Species, Aggregated, and Glycoproteomic datasets, demonstrate that TSARseqNovo outperforms state-of-the-art models, including CasaNovo, NovoB, InstaNovo + , and π-HelixNovo. Specifically, TSARseqNovo achieves up to a 2-fold speed increase over CasaNovo and π-HelixNovo, and approximately 10-fold over NovoB and InstaNovo + , while also showing substantial improvements in peptide prediction precision, especially for long peptides. These advancements position TSARseqNovo as a powerful tool for accelerating high-throughput proteomics research and addressing increasingly complex biological questions.

Indexed as

PeptidesProteomicsSequence Analysis, ProteinAlgorithmsHumansSoftwarePeptides

Identifiers

PMID39948275
PMCPMC11825679

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.